

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Recombinant Human NovoNectin EBT-EPT094

Article Name	Recombinant Human NovoNectin
Biozol Catalog Number	EBT-EPT094
Supplier Catalog Number	EPT094
Alternative Catalog Number	EBT-EPT094-50
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	Recombinant Human Fibronectin Fragment is produced by our E.coli expression system and the target gene encoding Pro1270-Ser1546&Ala1721-Thr2016 is expressed....
Molecular Weight	Molecular weight: 62.7 KDa. Apparent molecular weight: 60-80 KDa, reducing conditions
UniProt	P02751
Purity	Greater than 95% as determined by reducing SDS-PAGE.

Application Notes	Redissolve: Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. Biological activity: Measured by its ability to support cell attachment and spreading when used as a substratum for cell culture. The ED50 for this effect is 0.1-0.5 ug/ml. Background: Fibronectin1(FN1) is a secreted protein and contains 12 fibronectin type-I domains, fibronectin type-II domains and 16 fibronectin type-III domains. Recombinant human fibronectin fragment, is a protein of ~63 kDa containing a central cell-binding domain, a high affinity heparin-binding domain II, and CS1 site within the alternatively spliced III CS region of human fibronectin. Cells bind to a VLA-4 ligand, a CS-I site, and a VLA-5 ligand, a cell attachment domain, and virus vectors binds to a heparin binding domain II, which co-locates the cell and the virus vector on NovoNectin. This process enhances the density of both cells and vectors, and facilitates the gene transduction in the result
-------------------	--